IRIS Accounts Production v24.2.0.383 11653779 Board of Directors 1.6.23 31.5.24 31.5.24 false true false false false true false Ordinary 1.00000 A Ordinary 1.00000 B Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh116537792023-05-31116537792024-05-31116537792023-06-012024-05-31116537792022-05-31116537792022-06-012023-05-31116537792023-05-3111653779ns15:EnglandWales2023-06-012024-05-3111653779ns14:PoundSterling2023-06-012024-05-3111653779ns10:Director12023-06-012024-05-3111653779ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3111653779ns10:SmallEntities2023-06-012024-05-3111653779ns10:AuditExemptWithAccountantsReport2023-06-012024-05-3111653779ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3111653779ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3111653779ns10:FullAccounts2023-06-012024-05-311165377912023-06-012024-05-3111653779ns10:OrdinaryShareClass12023-06-012024-05-3111653779ns10:OrdinaryShareClass22023-06-012024-05-3111653779ns10:OrdinaryShareClass32023-06-012024-05-3111653779ns10:Director22023-06-012024-05-3111653779ns10:Director32023-06-012024-05-3111653779ns10:RegisteredOffice2023-06-012024-05-3111653779ns5:CurrentFinancialInstruments2024-05-3111653779ns5:CurrentFinancialInstruments2023-05-3111653779ns5:Non-currentFinancialInstruments2024-05-3111653779ns5:Non-currentFinancialInstruments2023-05-3111653779ns5:ShareCapital2024-05-3111653779ns5:ShareCapital2023-05-3111653779ns5:RetainedEarningsAccumulatedLosses2024-05-3111653779ns5:RetainedEarningsAccumulatedLosses2023-05-3111653779ns5:NetGoodwill2023-06-012024-05-3111653779ns5:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3111653779ns5:PlantMachinery2023-06-012024-05-3111653779ns5:NetGoodwill2023-05-3111653779ns5:NetGoodwill2024-05-3111653779ns5:NetGoodwill2023-05-3111653779ns5:LandBuildings2023-05-3111653779ns5:PlantMachinery2023-05-3111653779ns5:LandBuildings2023-06-012024-05-3111653779ns5:LandBuildings2024-05-3111653779ns5:PlantMachinery2024-05-3111653779ns5:LandBuildings2023-05-3111653779ns5:PlantMachinery2023-05-3111653779ns5:CostValuation2023-05-3111653779ns5:WithinOneYearns5:CurrentFinancialInstruments2024-05-3111653779ns5:WithinOneYearns5:CurrentFinancialInstruments2023-05-3111653779ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-05-3111653779ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-05-3111653779ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-05-3111653779ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-05-3111653779ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2024-05-3111653779ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2023-05-3111653779ns5:Secured2024-05-3111653779ns5:Secured2023-05-3111653779ns10:OrdinaryShareClass12024-05-3111653779ns10:OrdinaryShareClass22024-05-3111653779ns10:OrdinaryShareClass32024-05-31
REGISTERED NUMBER: 11653779 (England and Wales)















Unaudited Financial Statements for the Year Ended 31st May 2024

for

FAMPHARM LIMITED

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)






Contents of the Financial Statements
for the year ended 31st May 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountants' Report 11

FAMPHARM LIMITED

Company Information
for the year ended 31st May 2024







DIRECTORS: K Thakrar
R Morjaria
N Radia





REGISTERED OFFICE: 2 Burton House
Repton Place
White Lion Road
Amersham
Buckinghamshire
HP7 9LP





REGISTERED NUMBER: 11653779 (England and Wales)





ACCOUNTANTS: Jacquards
2 Burton House
Repton Place
White Lion Road
Amersham
Buckinghamshire
HP7 9LP

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Balance Sheet
31st May 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 2,394,524 2,708,866
Tangible assets 5 7,510 9,668
Investments 6 100 100
2,402,134 2,718,634

CURRENT ASSETS
Stocks 131,949 243,163
Debtors 7 777,163 1,035,186
Cash at bank and in hand 249,263 155,705
1,158,375 1,434,054
CREDITORS
Amounts falling due within one year 8 2,270,267 2,392,650
NET CURRENT LIABILITIES (1,111,892 ) (958,596 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,290,242

1,760,038

CREDITORS
Amounts falling due after more than one
year

9

(1,384,941

)

(1,548,591

)

PROVISIONS FOR LIABILITIES (1,934 ) (1,934 )
NET (LIABILITIES)/ASSETS (96,633 ) 209,513

CAPITAL AND RESERVES
Called up share capital 11 300 300
Retained earnings (96,933 ) 209,213
SHAREHOLDERS' FUNDS (96,633 ) 209,513

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st May 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Balance Sheet - continued
31st May 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 31st May 2025 and were signed on its behalf by:





K Thakrar - Director


FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements
for the year ended 31st May 2024

1. STATUTORY INFORMATION

Fampharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Fampharm Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 401 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertaking are included by full consolidation in the consolidated financial statements of its parent, , .

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed fifteen years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost and 25% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.


FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements - continued
for the year ended 31st May 2024

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 19 (2023 - 12 ) .

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements - continued
for the year ended 31st May 2024

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1st June 2023
and 31st May 2024 3,143,418
AMORTISATION
At 1st June 2023 434,552
Charge for year 314,342
At 31st May 2024 748,894
NET BOOK VALUE
At 31st May 2024 2,394,524
At 31st May 2023 2,708,866

The Company has hived-up its subsidiary. The policy is to transfer the trade and net assets of the acquired subsidiaries in question to the Company at book value. The initial cost of the Company's investment in the subsidiary undertaking reflects the underlying fair value of its net assets and goodwill at the time of its acquisition.

As a result of the transfer, the value of the Company's investment in the subsidiary undertaking falls below the amount at which it is stated in the Company's accounting records. Section 396 of the Companies Act 2006 requires that the investment be written down accordingly and that the amount be charged as a loss in the Company's income statement. However, the directors consider that, as there has been no overall loss to the Company, it would fail to give a true and fair view to charge the diminution to the Company's income statement and it should instead be re-allocated to goodwill and the identifiable net assets transferred, so as to recognise, in the Company's individual statement of financial position, the effective cost to the Company of those net assets and goodwill. The effect on the Company's statement of financial position of this departure is to recognise goodwill at cost of £973,822 (2023: £973,822), less accumulated amortisation of £200,175 (2023: £102,792).

Given that the business concerned operates in a generally stable market, the directors have concluded that the estimated economic life of the resulting intangible asset is ten years at the date that the transfer took place.

The asset is reviewed annually for impairment and the last review indicated that no impairment had
arisen.

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements - continued
for the year ended 31st May 2024

5. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1st June 2023 4,135 12,865 17,000
Additions - 999 999
Disposals - (2,410 ) (2,410 )
At 31st May 2024 4,135 11,454 15,589
DEPRECIATION
At 1st June 2023 448 6,884 7,332
Charge for year 413 2,744 3,157
Eliminated on disposal - (2,410 ) (2,410 )
At 31st May 2024 861 7,218 8,079
NET BOOK VALUE
At 31st May 2024 3,274 4,236 7,510
At 31st May 2023 3,687 5,981 9,668

6. FIXED ASSET INVESTMENTS
Shares in
group
undertaking
£   
COST
At 1st June 2023
and 31st May 2024 100
NET BOOK VALUE
At 31st May 2024 100
At 31st May 2023 100

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements - continued
for the year ended 31st May 2024

6. FIXED ASSET INVESTMENTS - continued

The Company has hived-up its subsidiary. The policy is to transfer the trade and net assets of the acquired subsidiaries in question to the Company at book value. The initial cost of the Company's investment in the subsidiary undertaking reflects the underlying fair value of its net assets and goodwill at the time of its acquisition.

As a result of the transfer, the value of the Company's investment in the subsidiary undertaking falls below the amount at which it is stated in the Company's accounting records. Section 396 of the Companies Act 2006 requires that the investment be written down accordingly and that the amount be charged as a loss in the Company's income statement. However, the directors consider that, as there has been no overall loss to the Company, it would fail to give a true and fair view to charge the diminution to the Company's income statement and it should instead be re-allocated to goodwill and the identifiable net assets transferred, so as to recognise, in the Company's individual statement of financial position, the effective cost to the Company of those net assets and goodwill. The effect on the Company's statement of financial position of this departure is to recognise goodwill at cost of £973,822 (2023: £973,822), less accumulated amortisation of £200,175 (2023: £102,792).

Given that the business concerned operates in a generally stable market, the directors have concluded that the estimated economic life of the resulting intangible asset is ten years at the date that the transfer took place.

The asset is reviewed annually for impairment and the last review indicated that no impairment had
arisen.

7. DEBTORS
2024 2023
£    £   
Amounts falling due within one year:
Trade debtors 609,958 653,690
Amounts owed by group undertakings - 224,343
VAT 98,662 95,251
Prepayments 26,274 19,633
734,894 992,917

Amounts falling due after more than one year:
Other debtors 42,269 42,269

Aggregate amounts 777,163 1,035,186

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements - continued
for the year ended 31st May 2024

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 162,761 193,596
Trade creditors 547,079 611,507
Amounts owed to group undertakings 4,784 -
Amounts owed to participating interests 959,129 997,816
Corporation tax 84,956 112,527
Social security and other taxes 30,648 27,490
Other creditors 3,413 8,272
Directors' current accounts 14,320 14,320
Accruals and deferred income 463,177 427,122
2,270,267 2,392,650

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans - 1-2 years 141,180 171,194
Bank loans - 2-5 years 556,740 550,824
Bank loans more 5 yr by instal 687,021 826,573
1,384,941 1,548,591

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 687,021 826,573

10. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 1,547,702 1,742,187

The company's bank loans are secured by a fixed and floating charge over the company's and group's assets.

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
150 Ordinary 1.00 150 150
100 A Ordinary 1.00 100 100
50 B Ordinary 1.00 50 50
300 300

FAMPHARM LIMITED (REGISTERED NUMBER: 11653779)

Notes to the Financial Statements - continued
for the year ended 31st May 2024

12. ULTIMATE CONTROLLING PARTY

The immediate and ultimate parent company is Lotus Pharms Limited, a company incorporated in England & Wales, which holds 66.67% of the issued share capital of the company. There is no single ultimate controlling party.

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Fampharm Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Fampharm Limited for the year ended 31st May 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Fampharm Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Fampharm Limited and state those matters that we have agreed to state to the Board of Directors of Fampharm Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Fampharm Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Fampharm Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Fampharm Limited. You consider that Fampharm Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Fampharm Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Jacquards
2 Burton House
Repton Place
White Lion Road
Amersham
Buckinghamshire
HP7 9LP


31st May 2025